Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure (Q28306178)

9

0 references

Jos Beijnen

10

object named as

Jos H Beijnen

0 references

Alwin D R Huitema

11

object named as

Alwin D R Huitema

0 references

author name string

Thomas P C Dorlo

1

0 references

Suman Rijal

2

0 references

Bart Ostyn

3

0 references

Peter J de Vries

4

0 references

Rupa Singh

5

0 references

Narayan Bhattarai

6

0 references

Jean-Claude Dujardin

Journal of Infectious Diseases

8

0 references

language of work or name

English

0 references

publication date

1 July 2014

0 references

published in

0 references

volume

210

0 references

issue

1

0 references

page(s)

146-53

0 references

cites work

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Optimal dosing of miltefosine in children and adults with visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Opinion: the pharmacometrics of infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Modeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claims

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Quantification of lean bodyweight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU039

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIU039

1 reference

Consolidated OpenCitations Corpus – April 2017

release_u4kbeuuvs5hm5eemeq4pmbxiwe

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/u4kbeuuvs5hm5eemeq4pmbxiwe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

24443541

1 reference

Consolidated OpenCitations Corpus – April 2017